In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1

References

• F. Islami, L.A. Torre, and A. Jemal, Global trends of lung cancer mortality and smoking prevalence, Trans. Lung Cancer Res. 4 (2015), pp. 327–338.
   Web of Science ®Google Scholar
• Current Gastroenterology Reports, Changing Trends in Stomach Cancer Throughout the World, 2017.
   Google Scholar
• L.A. Torre, R.L. Siegel, E.M. Ward, and A. Jemal, Global cancer incidence and mortality rates and trends – An update, Cancer Epidemiol. Biomarkers Prev. 25 (2016), pp. 16–27.
   PubMed Web of Science ®Google Scholar
• J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, and F. Bray, Cancer incidence and mortality worldwide : Sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer 136 (2014), pp. E359–E386.
   Google Scholar
• R.L. Siegel, K.D. Miller, and A. Jemal, Cancer statistics, CA Cancer J. Clin. 66 (2016), pp. 7–30.
   Google Scholar
• G. Bottai, B. Pasculli, G.A. Calin, and L. Santarpia, Targeting the microRNA-regulating DNA damage/repair pathways in cancer, Expert Opin. Biol. Ther. 14 (2014), pp. 1667–1683.
   Google Scholar
• B. Groner and A. Weiss, Targeting survivin in cancer: Novel drug development approaches, BioDrugs 28 (2014), pp. 27–39.
   Google Scholar
• I. Antony-Debré, A. Paul, J. Leite, K. Mitchell, H.M. Kim, L.A. Carvajal, T.I. Todorova, K. Huang, A. Kumar, A.A. Farahat, B. Bartholdy, S. Narayanagari, J. Chen, A. Ambesi-Impiombato, A.A. Ferrando, I. Mantzaris, E. Gavathiotis, A. Verma, B. Will, D.W. Boykin, W.D. Wilson, G.M.K. Poon, and U. Steidl, Pharmacological inhibition of the transcription factor PU.1 in leukemia, J. Clin. Invest. 127 (2017), pp. 4297–4313.
   Google Scholar
• L. Chen, J.K. Morrow, H.T. Tran, S.S. Phatak, L. Du-Cuny, and S. Zhang, From laptop to benchtop to bedside: Structure-based drug design on protein targets, Curr. Pharm. Des. 18 (2012), pp. 1217–1239.
   Google Scholar
• A.C. Anderson, The process of structure-based drug design, J. Chem. Biol. 10 (2003), pp. 787–797.
   PubMed Web of Science ®Google Scholar
• C.H. Lee, H.C. Huang, and H.F. Juan, Reviewing ligand-based rational drug design: The search for an ATP synthase inhibitor, Int. J. Mol. Sci. 12 (2011), pp. 5304–5318.
   Google Scholar
• X. Dong and Z. Weng, The correlation between histone modifications and gene expression, Epigenomics 5 (2013), pp. 113–116.
   Google Scholar
• J. Gil, A. Ramirez-Torres and S. Encarnacion-Guevara, Lysine acetylation and cancer: A proteomics perspective, J. Proteomics 150 (2017), pp. 297–309.
   PubMed Web of Science ®Google Scholar
• T. Fujisawa and P. Filippakopoulos, Functions of bromodomain-containing proteins and their roles in homeostasis and cancer, Nat. Rev. Mol. Cell Biol. 18 (2017), pp. 246–262.
   Google Scholar
• T. Ran, Z. Zhang, K. Liu, Y. Lu, H. Li, J. Xu, X. Xiong, Y. Zhang, A. Xu, S. Lu, H. Liu, T. Lu, and Y. Chen, Insight into the key interactions of bromodomain inhibitors based on molecular docking, interaction fingerprinting, molecular dynamics and binding free energy calculation, Mol. Biosyst. 11 (2015), pp. 1295–1304.
   Google Scholar
• S. Mujtaba, L. Zeng, and M. Zhou, Structure and acetyl-lysine recognition of the bromodomain, Oncogene 26 (2007), pp. 5521–5527.
   Google Scholar
• B.K. Allen, S. Mehta, S.W.J. Ember, E. Schonbrunn, N. Ayad, and S.C. Schürer, Large-scale computational screening identifies first in class multitarget inhibitor of EGFR kinase and BRD4, Sci. Rep. 5 (2015), pp. 1–16.
   Google Scholar
• D.J. Owen, P. Ornaghi, J.C. Yang, N. Lowe, P.R. Evans, P. Ballario, D. Neuhaus, P. Filetici, and A. Travers, The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p, EMBO J. 19 (2000), pp. 6141–6149.
   Google Scholar
• C. Muvva, E.R.A. Singam, S.S. Raman, and V. Subramanian, Structure-based virtual screening of novel, high-affinity BRD4 inhibitors, Mol. Biosyst. 10 (2014), pp. 2384–2397.
   Google Scholar
• O. Goundiam, P. Gestraud, T. Popova, T. De, M. Rouge, V. Fourchotte, C. Houdayer, and S. Roman-Roman, Overexpression of CCNE1 and BRD4 genes in non-BRCAness, Int. J. Cancer 137 (2015), pp. 1890–1900.
   Google Scholar
• H. Herrmann, K. Blatt, J. Shi, K.V Gleixner, L. Müllauer, C.R. Vakoc, W.R. Sperr, H. Horny, J.E. Bradner, J. Zuber, and P. Valent, Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML) ABSTRACT, Oncotarget 3 (2012), pp. 1588–1599.
   Google Scholar
• J.E. Delmore, G.C. Issa, M.E. Lemieux, P.B. Rahl, J. Shi, H.M. Jacobs, E. Kastritis, T. Gilpatrick, R.M. Paranal, J. Qi, M. Chesi, A.C. Schinzel, M.R. McKeown, T.P. Heffernan, C.R. Vakoc, P.L. Bergsagel, I.M. Ghobrial, P.G. Richardson, R.A. Young, W.C. Hahn, K.C. Anderson, A.L. Kung, J.E. Bradner, and C.S. Mitsiades, BET bromodomain inhibition as a therapeutic strategy to target c-Myc, Cell 146 (2011), pp. 904–917.
   Google Scholar
• C.A. French, NUT midline carcinoma, Cancer Genet. Cytogenet. 203 (2011), pp. 16–20.
   Google Scholar
• G. Zhang, S.G. Smith, and M.M. Zhou, Discovery of chemical inhibitors of human bromodomains, Chem. Rev. 115 (2015), pp. 11625–11668.
   PubMed Web of Science ®Google Scholar
• W.W. Lockwood, K. Zejnullahu, J.E. Bradner, and H. Varmus, Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins, Proc. Natl. Acad. Sci. U.S.A. 109 (2012), pp. 19408–19413.
   Google Scholar
• Sachchidanand, L. Resnick-Silverman, S. Yan, S. Mutjaba, W.J. Liu, L. Zeng, J. J. Manfredi, and M.M. Zhou, Target structure-based discovery of small molecules that block human p53 and CREB binding protein association, Chem. Biol. 13 (2006), pp. 81–90.
   Google Scholar
• J. C. Borah, S. Mujtaba, I. Karakikes, L. Zeng, M. Muller, J. Patel, N. Moshkina, K. Morohashi, W. Zhang, R. J. Hajjar, and M. Zhou, A small molecule binding to the co-activator CREB-binding protein blocks apoptosis in cardiomyocytes, Chem Biol 18 (2012), pp. 531–541.
   Google Scholar
• J.J. Naveja and J.L. Medina-Franco, Insights from pharmacological similarity of epigenetic targets in epipolypharmacology, Drug Discov. Today 23 (2018), pp. 141–150.
   Google Scholar
• J.A. Mertz, A.R. Conery, B.M. Bryant, P. Sandy, S. Balasubramanian, D.A. Mele, L. Bergeron, and R.J. Sims, Targeting MYC dependence in cancer by inhibiting BET bromodomains, Proc. Natl. Acad. Sci. U. S. A. 108 (2011), pp. 16669–16674.
   PubMed Web of Science ®Google Scholar
• P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W.B. Smith, O. Fedorov, E.M. Morse, T. Keates, T.T. Hickman, I. Felletar, M. Philpott, S. Munro, M.R. McKeown, Y. Wang, A.L. Christie, N. West, M.J. Cameron, B. Schwartz, T.D. Heightman, N. La Thangue, C.A French, O. Wiest, A.L. Kung, S. Knapp, and J.E. Bradner, Selective inhibition of BET bromodomains, Nature 468 (2010), pp. 1067–1073.
   Google Scholar
• J. Seal, Y. Lamotte, F. Donche, A. Bouillot, O. Mirguet, F. Gellibert, E. Nicodeme, G. Krysa, J. Kirilovsky, S. Beinke, S. McCleary, I. Rioja, P. Bamborough, C.W. Chung, L. Gordon, T. Lewis, A.L. Walker, L. Cutler, D. Lugo, D.M. Wilson, J. Witherington, K. Lee, and R.K. Prinjha, Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A), Bioorg. Med. Chem. Lett. 22 (2012), pp. 2968–2972.
   PubMed Web of Science ®Google Scholar
• Y. Zhao, C.Y. Yang, and S. Wang, The making of i-bet762, a BET bromodomain inhibitor now in clinical development, J. Med. Chem. 56 (2013), pp. 7498–7500.
   Web of Science ®Google Scholar
• R. Sanchez, M. Jamel, and M.-M. Zhou, The bromodomain: From epigenome reader to druggable target, Biochim. Biophys Acta. 1839 (2015), pp. 676–685.
   Google Scholar
• C.Y. Fong, O. Gilan, E.Y.N. Lam, A.F. Rubin, S. Ftouni, D. Tyler, K. Stanley, D. Sinha, P. Yeh, J. Morison, G. Giotopoulos, D. Lugo, P. Jeffrey, S.C.W. Lee, C. Carpenter, R. Gregory, R.G. Ramsay, S.W. Lane, O. Abdel-Wahab, T. Kouzarides, R.W. Johnstone, S.J. Dawson, B.J.P. Huntly, R.K. Prinjha, A.T. Papenfuss, and M.A. Dawson, BET inhibitor resistance emerges from leukaemia stem cells, Nature 525 (2015), pp. 538–542.
   Google Scholar
• B. Raux, Y. Voitovich, C. Derviaux, A. Lugari, E. Rebuffet, S. Milhas, S. Priet, T. Roux, E. Trinquet, J.C. Guillemot, S. Knapp, J. M. Brunel, A.Y. Fedorov, Y. Collette, P. Roche, S. Betzi, S. Combes, and X. Morelli, Exploring selective inhibition of the first bromodomain of the human bromodomain and extra-terminal domain (BET) proteins, J. Med. Chem. 59 (2016), pp. 1634–1641.
   Web of Science ®Google Scholar
• Protein Preparaton Wizard, Epik, Schrödinger, LLC, NY. 2016.
   Google Scholar
• Prime, Schrödinger, LLC, NY. 2016.
   Google Scholar
• W.L. Jorgensen, D.S. Maxwell, and J. Tirado-rives, Development and testing of the OPLS All-atom force field on conformational energetics and properties of organic liquids, J. Am. Chem. Soc. 7863 (1996), pp. 11225–11236.
   Web of Science ®Google Scholar
• D.R. Roe and T.E. Cheatham, PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data, J. Chem. Theory Comput. 9 (2013), pp. 3084–3095.
   PubMed Web of Science ®Google Scholar
• S.A. Shiryaev, A.V Cheltsov, K. Gawlik, B.I. Ratnikov and A.Y. Strongin, Virtual ligand screening of the National Cancer Institute (NCI) compound library leads to the allosteric inhibitory scaffolds of the West Nile Virus NS3 proteinase, Assay Drug Dev. Technol. 9 (2011), pp. 69–78.
   Google Scholar
• M. Vassilios, P.F. Cartron, Z. Liutkeviciute, S. Klimasauskas, D. Matulis, C. Bronner, N. Martinet, and E. Mikros, Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation, Eur. J. Med. Chem. 114 (2016), pp. 390–396.
   Web of Science ®Google Scholar
• J. Gasteiger and J. Sadowski, Chemical information in 3D space, J. Chem. Inf. Comput. Sci. 36 (1996), pp. 1030–1037.
   Google Scholar
• Schrödinger Release 2016-1, LigPrep, Schrödinger, LLC, NY, 2016.
   Google Scholar
• I. Chen and N. Foloppe, Drug-like bioactive structures and conformational coverage with the LigPrep/ConfGen Suite: Comparison to programs MOE and Catalyst, J. Chem. Inf. Model. 50 (2010), pp. 822–839.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2016-1, Epik, Schrödinger, LLC, NY, 2016.
   Google Scholar
• Schrödinger Release 2016-1, Glide, Schrödinger, LLC, NY, 2016.
   Google Scholar
• R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, J.K. Perry, D.E. Shaw, P. Francis, and P.S. Shenkin, Glide – A new approach for rapid, accurate docking and scoring, 1. Method and assessment of docking accuracy. J. Med. Chem. 47 (2004), pp. 1739–1749.
   Web of Science ®Google Scholar
• R.A. Friesner, R.B. Murphy, M.P. Repasky, L.L. Frye, J.R. Greenwood, T.A. Halgren, P.C. Sanschagrin, and D.T. Mainz, Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes, J. Med. Chem. 49 (2006), pp. 6177–6196.
   Web of Science ®Google Scholar
• R. Wang, L. Lai and S. Wang, Further development and validation of empirical scoring functions for structure-based binding affinity prediction, J. Comput. Aided Mol. Des. 16 (2002), pp. 11–26.
   PubMed Web of Science ®Google Scholar
• P.A.K. D.A. Case, R.M. Betz, W. Botello-Smith, D.S. Cerutti, T.E. Cheatham III, T.A. Darden, R.E. Duke, T.J. Giese, H. Gohlke, A.W. Goetz, N. Homeyer, S. Izadi, P. Janowski, J. Kaus, A. Kovalenko, T.S. Lee, S. LeGrand, P. Li, C. Lin, T. Luchko, R. Luo, B. Madej, AMBER 2016, Univ. Calif. San Fr.
   Google Scholar
• J. Wang, W. Wang, P.A. Kollman, and D.A. Case, Automatic atom type and bond type perception in molecular mechanical calculations, J. Mol. Graph. Model. 25 (2006), pp. 247–260.
   PubMed Web of Science ®Google Scholar
• J. Wang, R.M. Wolf, J.W. Caldwell, P.A. Kollman, and D.A. Case, Development and testing of a general amber force field, J. Comput. Chem. 25 (2004), pp. 1157–1174.
   Google Scholar
• C. Simmerling, ff 14SB: Improving the accuracy of protein side chain and backbone parameters from ff 99SB, J. Chem. Theory Comput. 11 (2015), pp. 3696–3713.
   PubMed Web of Science ®Google Scholar
• P.A. Kollman, I. Massova, C. Reyes, B. Kuhn, S. Huo, L. Chong, M. Lee, T. Lee, Y. Duan, W. Wang, O. Donini, P. Cieplak, J. Srinivasan, D.A. Case, and T.E. Cheatham, Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models, Acc. Chem. Res. 33 (2000), pp. 889–897.
   PubMed Web of Science ®Google Scholar
• S. Genheden and U. Ryde, The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities, Expert Opin. Drug Discov. 10 (2015), pp. 449–461.
   Google Scholar
• B.R. Miller, T.D. Mcgee, J.M. Swails, N. Homeyer, H. Gohlke, and A.E. Roitberg, MMPBSA.py : An efficient program for end-state free energy calculations, J. Chem. Theory Comput. 8 (2012), pp. 3314–3321.
   Google Scholar
• P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W.B. Smith, O. Fedorov, E.M. Morse, T. Keates, T.T. Hickman, I. Felletar, M. Philpott, S. Munro, M.R. McKeown, Y. Wang, A.L. Christie, N. West, M.J. Cameron, B. Schwartz, T.D. Heightman, N. La Thangue, C.A. French, O. Wiest, A.L. Kung, S. Knapp, and J.E. Bradner, Selective inhibition of BET bromodomains, Nature 468 (2010), pp. 1067–1073.
   Google Scholar
• S.M.F. Mahender B. Dewal, A.S. Wani, C.Vidaillac, D. Oupicky, and M.J. Rybak, Thieno[2,3-d]pyrimidinedione derivatives as antibacterial agents, Eur. J. Med. Chem. 51 (2013), pp. 145–153.
   Google Scholar
• T. Gregoric, M. Sedic, P. Grbcic, A.Tomljenovic Paravic, S. Kraljevic Pavelic, M. Cetina, and R. Vianello, Novel pyrimidine-2,4-dionee1,2,3-triazole and furo[2,3-d]pyrimidine- 2-onee1,2,3-triazole hybrids as potential anti-cancer agents: Synthesis, computational and X-ray analysis and biological evaluation, Eur. J. Med. Chem. 125 (2017), pp. 1247–1267.
   Web of Science ®Google Scholar
• C.H. Peptide, E.M. Flynn, O.W. Huang, F. Poy, S.F. Bellon, Y. Tang, A.G. Cochran, E.M. Flynn, O.W. Huang, F. Poy, M. Oppikofer, S.F. Bellon, and Y. Tang, A subset of human bromodomains recognizes butyryllysine and crotonyllysine histone peptide modifications, Cell 23 (2015), pp. 1801–1814.
   Google Scholar
• M. Jung, M. Philpott, S. Müller, J. Schulze, V. Badock, U. Eberspächer, D. Moosmayer, B. Bader, N. Schmees, A. Fernández-Montalván, and B. Haendler, Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1, J. Biol. Chem. 289 (2014), pp. 9304–9319.
   Web of Science ®Google Scholar
• J. Su, X. Liu, S. Zhang, F. Yan, Q. Zhang, and J. Chen, A computational insight into binding modes of inhibitors XD29, XD35, and XD28 to bromodomain-containing protein 4 based on molecular dynamics simulations, J. Biomol. Struct. Dyn. 36 (2018), pp. 1212–1224.
   PubMed Web of Science ®Google Scholar
• J.E. Ladbury, Just add water! The effect of water on the specificity of protein- ligand binding sites And its potential application to drug design, Chem. Biol. 3 (1996), pp. 973–980.
   Google Scholar
• N.M. Levinson and S.G. Boxer, A conserved water-mediated hydrogen bond network defines bosutinib’s kinase selectivity, Nat. Chem. Biol 10 (2014), pp. 127–132.
   Google Scholar
• A.T. García-Sosa and R.L. Mancera, Free energy calculations of mutations involving a tightly bound water molecule and ligand substitutions in a ligand-protein complex, Mol. Inform. 29 (2010), pp. 589–600.
   Google Scholar
• J. Michel, J. Tirado-rives, and W.L. Jorgensen, Energetics of displacing water molecules from protein binding sites: Consequences for ligand optimization, J. Am. Chem. Soc. 131 (2010), pp. 15403–15411.
   Web of Science ®Google Scholar